Posted on

Low level of innovation and generic competition to result in the neuroendocrine tumor market growing only 0.9% by 2030, says GlobalData


The market for neuroendocrine tumors (NETs) – a rare type of tumor where cancerous growth can begin in any cell within the hormone or nervous system – is expected to see a very slow 0.9% compound annual growth rate (CAGR) over the next decade in the world’s eight major markets (8MM*) due to substantial generic erosion and low levels of innovation, according to GlobalData. The leading data and analytics company notes that this may turn around after 2030 with the development of molecules currently in the early-stage pipeline.
According to GlobalData’s latest report, ‘Neuroendocrine Tumors – Global Drug Forecast and Market Analysis to 2030’, …

Read More